56-OR

Abstract

Objectives To evaluate if placental histopathological changes of vascular insufficiency correlate with circulating angiogenic factors in patients with preeclampsia. Methods Subjects were selected from a previous prospective cohort study of preeclampsia based on availability of plasma anti-angiogenic factor (sFlt1) and pro-angiogenic factor (PlGF) measurements and placental histology specimens. Preeclamptic patients were divided into two groups based on plasma levels of these factors described as a ratio; anti-angiogenic preeclampsia with sFlt1/PlGF ratio ⩾85 and normal angiogenic preeclampsia with sFlt1/PlGF n (%) when appropriate. Results The anti-angiogenic preeclampsia group ( N = 48) presented at an earlier gestational age (weeks) than the normal angiogenic group ( N = 28); {32 (28, 34) vs. 35 (32, 36), P = 0.002}, had higher systolic blood pressure (mmHg) {154 (147, 168) vs. 147 (132, 158), P = 0.02}, delivered early (weeks) {(32 (29, 34) vs. 36 (34, 37), P P P P = 0.002} and syncytial knots {81.3% vs. 39.3%, P Conclusions Preeclamptic patients with imbalance in circulating angiogenic factors have disproportionally higher rates of placental vascular lesions historically associated with severe disease. Disclosures K. Baltajian: None. J.L. Hecht: None. J.B. Wenger: None. S. Salahuddin: None. S.S. Verlohren: Consultant, Research Support Recipient, Commercial Interest: Roche Diagnostics, ThermoFisher, Novartis. F.H. Perschel: None. Z.K. Zsengeller: None. R. Thadhani: named as co-inventors of patents related to use of angiogenic biomarkers in preeclampsia that are held by Harvard Hospitals, has financial interest in Aggamin LLC. S. Karumanchi: named as co-inventors of patents related to use of angiogenic biomarkers in preeclampsia that are held by Harvard Hospitals, S.A.K has financial interest in Aggamin LLC, Consultant to Siemens, and Roche diagnostics. S. Rana: None.